Document Detail


Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.
MedLine Citation:
PMID:  7831179     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure. It is generally thought that doses below 500-550 mg/m2 are safe but, when objective measures of cardiac function are used, it becomes apparent that degrees of cardiac failure occur at doses below this. We present here the case histories of two patients who developed very severe cardiac failure at cumulative doses well below 500 mg/m2 but who survived their initial cardiac illness due to aggressive intervention. In one case, the patient was successfully treated by orthotopic cardiac transplantation.
Authors:
S Sriskandan; M E O'Brien; I E Smith; P Collins; M E Gore
Related Documents :
20513729 - Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.
20486829 - Growth hormone and testosterone in heart failure therapy.
424569 - The sella turcica in primary end organ failure.
18645329 - Design and rationale of the urgent dyspnea study: an international, multicenter, prospe...
19808269 - Osteopontin, a new prognostic biomarker in patients with chronic heart failure.
9456189 - Age and left ventricular ejection fraction identify patients with advanced breast cance...
21090529 - Prediction and stratification of the future cardiovascular arrhythmic events: signal av...
11484759 - Excimer laser coronary angioplasty (elca) for diffuse in-stent restenosis: beneficial l...
7834729 - Catheter sizes for quantitative coronary arteriography.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Postgraduate medical journal     Volume:  70     ISSN:  0032-5473     ISO Abbreviation:  Postgrad Med J     Publication Date:  1994 Oct 
Date Detail:
Created Date:  1995-02-22     Completed Date:  1995-02-22     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0234135     Medline TA:  Postgrad Med J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  759-61     Citation Subset:  IM    
Affiliation:
Department of Medicine, Royal Marsden Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Cardiomyopathy, Dilated / chemically induced*,  therapy*
Dose-Response Relationship, Drug
Doxorubicin / administration & dosage,  adverse effects*
Drug Administration Schedule
Female
Heart Transplantation
Humans
Lymphoma, B-Cell / drug therapy
Middle Aged
Rhabdomyosarcoma, Embryonal / drug therapy
Chemical
Reg. No./Substance:
23214-92-8/Doxorubicin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Microembolism from aortic aneurysm and ventricular thrombus: a complication of intravenous streptoki...
Next Document:  Bilateral foot drop, weight loss and rectal bleeding as an acute presentation of Crohn's disease.